Trials / Completed
CompletedNCT03492333
Gluten Free Diet in IBS Patients Stratified According to Their Antigliadin Status
The Role of Antigliadin Antibodies in Predicting the Beneficial Effect of Gluten Free Diet in Unselected IBS Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- McMaster University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and also in adult patients with diagnosis of Irritable Bowel Syndrome (Rome III criteria). Antibodies to native gliadin (AGA) have been suggested as a potential diagnostic marker of response to GFD. However, this has not been tested in a prospective study in IBS patients. Identification of predictors of a symptomatic response to GFD within the IBS population would improve the clinical management of these patients. The purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal symptoms and gut motility in patients with Irritable Bowel Syndrome stratified according to their antigliadin antibodies status. Additional purposes include investigating effects gluten free diet may have on other parameters: * Improvement of mood * Quality of life and general well-being * Changes in gut microbiota
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Gluten free diet | Gluten-free diet- Instructions provided by a dietitian |
Timeline
- Start date
- 2012-04-30
- Primary completion
- 2016-05-30
- Completion
- 2016-05-30
- First posted
- 2018-04-10
- Last updated
- 2018-04-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03492333. Inclusion in this directory is not an endorsement.